Leishmaniasis visceral
ICD-10 B55.0 is a billable code used to indicate a diagnosis of leishmaniasis visceral.
Leishmaniasis visceral, also known as kala-azar, is a severe form of leishmaniasis caused by protozoan parasites of the genus Leishmania, primarily Leishmania donovani and Leishmania infantum. This disease is transmitted through the bite of infected female phlebotomine sandflies. The clinical presentation includes prolonged fever, weight loss, splenomegaly, hepatomegaly, and anemia. If left untreated, visceral leishmaniasis can be fatal, with a mortality rate exceeding 90% in untreated cases. Diagnosis is typically confirmed through serological tests, bone marrow aspiration, or splenic aspirate. Treatment protocols often involve the use of antimonial compounds, amphotericin B, or miltefosine, depending on the severity of the disease and the patient's health status. Early diagnosis and treatment are crucial to improving outcomes and reducing morbidity and mortality associated with this tropical disease.
Detailed clinical notes, laboratory results, and treatment plans must be documented.
Patients presenting with fever, splenomegaly, and weight loss after travel to endemic regions.
Ensure all laboratory tests are documented to support the diagnosis.
Complete blood counts and any relevant hematological findings should be included.
Patients with anemia and splenomegaly requiring evaluation for underlying causes.
Document any blood transfusions or treatments related to anemia.
Used when a biopsy is performed to confirm leishmaniasis.
Pathology report must be included.
Infectious disease specialists should ensure proper documentation of the biopsy site.
Common symptoms include prolonged fever, weight loss, splenomegaly, hepatomegaly, and anemia. Patients may also experience fatigue and night sweats.
